Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL450895 | 0.76 | GPR3 (0.34) | GPR3CYP1A2CYP2A6CYP2C19CYP19A1 | |
| SCHEMBL7459883 | 0.76 | GPR3 (0.34) | GPR3CYP1A2CYP2C19CYP19A1KDM4E | |
| SCHEMBL938097 | 0.76 | GPR3 (0.44) | GPR3CYP1A2CYP2A6CYP2C19CYP19A1 | |
| SCHEMBL4533455 | 0.70 | CYP1A2 (0.32) | CYP1A2CYP2A6POLB | |
| SCHEMBL7648214 | 0.64 | GPR3 (0.52) | GPR3CYP1A2CYP2A6CYP2C19CYP19A1 | |
| SCHEMBL19810738 | 0.64 | MAPK1 (0.40) | GPR3CYP1A2CYP2C19CYP19A1KDM4E | |
| SCHEMBL1537961 | 0.62 | MAPK1 (0.39) | GPR3CYP1A2CYP2C19CYP19A1KDM4E | |
| SCHEMBL23529688 | 0.59 | HTT (0.40) | GPR3CYP1A2CYP2A6CYP2C19CYP19A1 | |
| SCHEMBL8579432 | 0.59 | MAPK1 (0.40) | GPR3CYP1A2CYP2C19CYP19A1KDM4E | |
| SCHEMBL1618808 | 0.59 | GPR3 (0.52) | GPR3CYP1A2CYP2C19CYP19A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1341766-B1 | IMIDAZOLONE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES | HOFFMANN LA ROCHE (CH) | 2005-10-26 | — | — | EP | disclosed |
| EP-1341766-A1 | IMIDAZOLONE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-09-10 | — | — | EP | disclosed |
| US-6518293-B2 | Inhibitors of the human immunodeficiency virus reverse transcriptase enzyme which is involved in viral replication. | HOFFMANN-LA ROCHE INC. | 2003-02-11 | — | — | US | disclosed |
| US-20020107272-A1 | Anti-HIV imidazolone derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2002-08-08 | — | — | US | disclosed |
| WO-2002042279-A1 | IMIDAZOLONE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107272-A1 | Anti-HIV imidazolone derivatives | EIF2AK2, IMPDH1, POLR2E | GPR3 4195/4885CYP1A2 880/4885CYP2A6 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.